Dual HER2 inhibition and pathological complete response in early breast cancer: increasing success of treatment by improving patient selection

Ann Oncol. 2017 Mar 1;28(3):441-443. doi: 10.1093/annonc/mdx016.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized*
  • Breast Neoplasms*
  • Humans
  • Patient Selection
  • Trastuzumab

Substances

  • Antibodies, Monoclonal, Humanized
  • pertuzumab
  • Trastuzumab